- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06376409
Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females
July 7, 2025 updated by: Nutraceutical Wellness Inc.
A Single-center, Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females With Self-Perceived Thinning Hair
A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.
Study Overview
Status
Completed
Conditions
Detailed Description
A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.
All treatment regimens are commercially available nutraceutical hair growth supplements.
45 subjects will be enrolled into each of the 4 supplement groups.
Subjects will undergo a baseline, baseline + 48 hours, 90 day, 90 day + 48 hours, 180 day and 180 day + 48 hours visit and will have compliance phone calls at Days 45 and 135.
All subject data will be compared to baseline in paired comparison for each subject using a historical control.
Study Type
Interventional
Enrollment (Actual)
181
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95815
- Integrative Skin Science and Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Females of all Fitzpatrick skin, and hair types between 18-70 years of age with self-perceived thinning, confirmed by a dermatologist.
- Willing and able to adhere to the same dietary lifestyles for the duration of the study.
- Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
- General good health, as determined by the Investigator or qualified sub-investigator.
- Willing and able to attend all study visits and comply with the test product daily instructions.
- Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
- Willing and able to cooperate with the requirements of the study.
- Able to complete and understand the various questionnaires.
Exclusion Criteria:
- Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
- Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
- Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
- Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
- Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating.
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy.
- Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
- History of surgical correction of hair loss on the scalp (i.e., hair transplant).
- Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
- Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
- History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
- A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
- A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
- A known allergy to any of the ingredients in the investigational product.
- Utilization of low-level lasers for hair growth in the last three months.
- Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
- Known history of or current iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day as reported by the subject.
- Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nutrafol Hair Growth Supplement
4 commercially available hair growth nutraceuticals will be evaluated.
Treatment groups will be assigned according to the investigator's discretion.
Efficacy comparisons will not be made across treatment groups.
|
Hair growth supplement for women ages 18 - 44.
This product will be studied in the general women population and not postpartum women.
Hair growth supplement for women ages 18 - 44
Hair growth supplement for women ages 45 - 70
Hair growth supplement for women ages 18 - 44.
This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percent change in hair growth rate at Day 180 relative to baseline (Day 0)
Time Frame: 180 days
|
The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The percent change in hair growth rate at Day 90 relative to baseline (Day 0)
Time Frame: 90 Days
|
The percent change in hair growth rate at Day 90 relative to baseline (Day 0) as measured by the Canfield HairMetrix®.
|
90 Days
|
|
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days
Time Frame: 90 days
|
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days as measured by the Canfield HairMetrix® compared to baseline.
|
90 days
|
|
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days
Time Frame: 180 days
|
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days as measured by the Canfield HairMetrix® compared to baseline.
|
180 days
|
|
The change in terminal to vellus ratio
Time Frame: 90 Days
|
The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 90 days compared to baseline.
|
90 Days
|
|
The change in terminal to vellus ratio
Time Frame: 180 Days
|
The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 180 days compared to baseline.
|
180 Days
|
|
The change in anagen to telogen ratio
Time Frame: 90 Days
|
The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.
|
90 Days
|
|
The change in anagen to telogen ratio
Time Frame: 180 Days
|
The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.
|
180 Days
|
|
The change in average number of hairs per follicular unit
Time Frame: 90 Days
|
The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 90 days compared to baseline.
|
90 Days
|
|
The change in average number of hairs per follicular unit
Time Frame: 180 Days
|
The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 180 days compared to baseline.
|
180 Days
|
|
The change in total hair width per cm2
Time Frame: 90 Days
|
The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.
|
90 Days
|
|
The change in total hair width per cm2
Time Frame: 180 Days
|
The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.
|
180 Days
|
|
The change in mean inter-follicular distance
Time Frame: 90 Days
|
The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 90 days compared to baseline.
|
90 Days
|
|
The change in mean inter-follicular distance
Time Frame: 180 Days
|
The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 180 days compared to baseline.
|
180 Days
|
|
Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days
Time Frame: 90 Days
|
Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 90 days
|
90 Days
|
|
Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days
Time Frame: 180 Days
|
Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 180 days
|
180 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2024
Primary Completion (Actual)
June 18, 2025
Study Completion (Actual)
June 18, 2025
Study Registration Dates
First Submitted
April 11, 2024
First Submitted That Met QC Criteria
April 16, 2024
First Posted (Actual)
April 19, 2024
Study Record Updates
Last Update Posted (Actual)
July 9, 2025
Last Update Submitted That Met QC Criteria
July 7, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NW-HGN-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hair Thinning
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
DeNova ResearchTerminatedHair Loss | Hair ThinningUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
Nutraceutical Wellness Inc.TerminatedHair ThinningUnited States
-
Arbor Life LabsCompletedAndrogenetic Alopecia | Androgenic Alopecia | Hair Loss/Baldness | Hair Thinning | Telogen Effluvium | Thinning HairUnited States
-
Restore Biologics Holdings, Inc. dba XtresséActive, not recruitingAlopecia | Hair Loss | Thinning Hair | Thin HairUnited States
-
NovoBliss Research Pvt LtdZYWIE VENTURES PRIVATE LIMITEDCompletedHair Thinning | Hair Brittle | Dry HairIndia
-
Hungkuang UniversitySchweitzer Biotech CompanyActive, not recruitingAlopecia | Hair Condition | Hair Loss | Hair Thinning | Sebum Production | Scalp Health | Hair HealthTaiwan
-
Revision SkincareDermicoCompleted
Clinical Trials on Nutrafol Women's Postpartum Hair Growth Supplement
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
BrandiZoneCitruslabsCompletedHair Loss | Hair HealthUnited States
-
Nutraceutical Wellness Inc.CompletedHair ThinningUnited States
-
Olistic Research Labs S.L.RecruitingEarly Female Pattern Hair Loss (FPHL)Spain
-
Olistic Research Labs S.L.RecruitingEarly Female Pattern Hair Loss (FPHL)Germany
-
Olistic Research Labs S.L.CompletedEarly Female Pattern Hair Loss (FPHL)Spain
-
Olistic Research Labs S.L.Completed
-
Olistic Research Labs S.L.Grupo Dermatologico Y Estetico Pedro Jaen S.A.Recruiting